William Blair Has Positive Outlook for SPRY FY2024 Earnings

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Equities researchers at William Blair upped their FY2024 earnings per share (EPS) estimates for shares of ARS Pharmaceuticals in a report issued on Monday, November 4th. William Blair analyst L. Hanbury-Brown now anticipates that the company will post earnings of ($0.63) per share for the year, up from their previous forecast of ($0.68). William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.66) per share. William Blair also issued estimates for ARS Pharmaceuticals’ Q4 2024 earnings at ($0.20) EPS, Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.02 EPS and FY2025 earnings at ($0.19) EPS.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The business had revenue of $0.50 million during the quarter, compared to the consensus estimate of $2.00 million.

A number of other analysts have also recently issued reports on the company. Raymond James upgraded ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from $18.00 to $22.00 in a research report on Tuesday, August 13th. Leerink Partners boosted their price objective on ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a research report on Friday, September 20th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $30.00 price objective on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ARS Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $24.00.

ARS Pharmaceuticals Stock Up 0.8 %

Shares of NASDAQ SPRY opened at $15.32 on Wednesday. The business’s 50 day moving average is $14.09 and its two-hundred day moving average is $11.30. The company has a market cap of $1.49 billion, a P/E ratio of -32.60 and a beta of 0.90. ARS Pharmaceuticals has a 12 month low of $3.38 and a 12 month high of $17.08.

Insider Activity at ARS Pharmaceuticals

In related news, COO Brian Dorsey sold 50,000 shares of the business’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $15.00, for a total value of $750,000.00. Following the sale, the chief operating officer now owns 6,024 shares of the company’s stock, valued at $90,360. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, COO Brian Dorsey sold 50,000 shares of the business’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $15.00, for a total value of $750,000.00. Following the sale, the chief operating officer now owns 6,024 shares of the company’s stock, valued at $90,360. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Richard E. Lowenthal sold 100,000 shares of the business’s stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $12.93, for a total value of $1,293,000.00. Following the completion of the transaction, the chief executive officer now directly owns 1,398,499 shares in the company, valued at approximately $18,082,592.07. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,055,895 shares of company stock valued at $14,619,032 in the last 90 days. 40.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ARS Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of SPRY. nVerses Capital LLC acquired a new position in ARS Pharmaceuticals in the third quarter worth $30,000. Russell Investments Group Ltd. acquired a new position in ARS Pharmaceuticals in the first quarter worth $60,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in ARS Pharmaceuticals by 151.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock worth $63,000 after purchasing an additional 4,472 shares in the last quarter. Principal Financial Group Inc. acquired a new position in shares of ARS Pharmaceuticals during the second quarter valued at $87,000. Finally, Paloma Partners Management Co acquired a new position in shares of ARS Pharmaceuticals during the first quarter valued at $103,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.